maker of tirzepatide FDA Says Compounded Must Exit the Market Zepbound (tirzepatide) FDA Approval History

For example, in the STEP 1 trial , patients taking semaglutide lost an average of 14.9% of their body weight over 68 weeks , compared with just 2.4% in the placebo group (NEJM study)

Choosing a multi-pack allows you to: Save more instantly compared to single kit purchases Lower your cost per kit as bundle size increases Qualify for free shipping on 600 pounds+ orders Stock up in advance with a long shelf life (expires 12/2029), you can store your supply with confidence Receive all supplies together , ready for use Multi-packs are ideal for users who already know they will continue beyond their first kit

A 2.5 mg starting dose of tirzepatide is roughly equivalent in clinical effect to a 0.25 mg starting dose of semaglutide, not because one is weaker, but because the molecular pharmacology demands different quantities to achieve similar receptor occupancy

Journal of Dermatology & Dermatologic Surgery , 23(4), 41-47